VANCOUVER, British Columbia, October 21, 2020 — Renaissance BioScience Corp., a leading global bioengineering company, is pleased to announce the appointment of Dr. Peter Lutwyche to the company’s board of directors.

Dr. Lutwyche is the Chief Executive Officer and President of Genevant Sciences Corporation. Previously, he was Chief Technology Officer and Vancouver Site Head for Genevant. Prior to joining Genevant, Peter was Chief Technology Officer of Arbutus Biopharma, where he led the development of the company’s nucleic acid-delivery technology. Before his experience at Arbutus, he was Head of Pharmaceutical Development at QLT, where he contributed to the development and commercialization of VISUDYNE®. Peter has over 20 years of experience in the field of nucleic acid-based products. Dr. Lutwyche holds a PhD in chemistry from the University of British Columbia and a BSc in chemistry from the University of Warwick.

“We’re pleased to welcome Dr. Lutwyche to the Renaissance board of directors. Peter brings tremendous scientific and commercial experience in the field of RNA delivery mechanisms to our board, as we move forward rapidly with the development of our novel technologies,” said Maurice Boucher, Renaissance Co-Founder and Executive Chairman.

Dr. Lutwyche comments: “I am intrigued by the potential of the Renaissance technology platform.  Joining the Renaissance board of directors at this time will allow me to be part of the development of this exciting platform and I look forward to adding my contribution to the company.”

Dr. John Husnik, Renaissance Co-Founder and CEO, comments: “We’re looking forward to interacting with Dr.  Lutwyche as we accelerate the advancement of our novel technologies. Peter’s breadth and depth of experience will be invaluable as we move forward not only with our research and development plans but also the commercialization of our high-value products.”

About Renaissance BioScience Corp.

Renaissance BioScience Corp. is developing novel proprietary technology for the oral delivery of bioactive molecules, targeting human and animal health solutions as well as environmentally safe agricultural crop protection. Based in Vancouver, Canada, Renaissance is a privately held bioengineering platform technology company that develops innovative, market-ready, functional microorganisms that provide solutions to a broad range of health, environmental and industrial problems.  Detailed information about the Renaissance group of companies can be accessed by visiting our website at www.renaissancebioscience.com.

Back to all news